Management of HCV in Dialysis Patients

Fabrizio Fabrizi, Paul Martin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

HCV infection remains frequent among patients on maintenance haemodialysis, and HCV has a detrimental role on survival in this population. Recent data have been accumulated on the antiviral treatment of HCV in dialysis patients. Although response rates to conventional interferon are better in the dialysis population, tolerance to interferon monotherapy appears lower in patients on maintenance haemodialysis than in the population with intact kidney function. The most frequent side effects requiring interruption of treatment were flu-like symptoms and gastrointestinal and haematological changes. One-third of dialysis patients with chronic HCV were successfully treated with conventional or pegylated interferon monotherapy, the summary estimate for sustained virological response rate being 39% (95% CI 32, 46) and 31% (95% CI 7, 55), respectively, according to a recent meta-analysis. Preliminary evidence does not support additional benefit of monotherapy with peginterferon on the viral response in the dialysis population. Scarce data exist on combined antiviral therapy for HCV (interferon plus ribavirin) in the dialysis population, even if encouraging results in terms of viral response have been noted. The optimal antiviral treatment of chronic hepatitis C in the dialysis population is currently under investigation.

Original languageEnglish
Title of host publicationClinical Dilemmas in Viral Liver Disease
PublisherWiley-Blackwell
Pages50-54
Number of pages5
ISBN (Print)9781405179058
DOIs
StatePublished - Mar 10 2010

Fingerprint

Dialysis
Interferons
Population
Antiviral Agents
Renal Dialysis
Maintenance
Ribavirin
Chronic Hepatitis C
Therapeutics
Meta-Analysis
Kidney
Survival
Infection

Keywords

  • Dialysis
  • Hepatitis C
  • Interferon
  • Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fabrizi, F., & Martin, P. (2010). Management of HCV in Dialysis Patients. In Clinical Dilemmas in Viral Liver Disease (pp. 50-54). Wiley-Blackwell. https://doi.org/10.1002/9781444319590.ch11

Management of HCV in Dialysis Patients. / Fabrizi, Fabrizio; Martin, Paul.

Clinical Dilemmas in Viral Liver Disease. Wiley-Blackwell, 2010. p. 50-54.

Research output: Chapter in Book/Report/Conference proceedingChapter

Fabrizi, F & Martin, P 2010, Management of HCV in Dialysis Patients. in Clinical Dilemmas in Viral Liver Disease. Wiley-Blackwell, pp. 50-54. https://doi.org/10.1002/9781444319590.ch11
Fabrizi F, Martin P. Management of HCV in Dialysis Patients. In Clinical Dilemmas in Viral Liver Disease. Wiley-Blackwell. 2010. p. 50-54 https://doi.org/10.1002/9781444319590.ch11
Fabrizi, Fabrizio ; Martin, Paul. / Management of HCV in Dialysis Patients. Clinical Dilemmas in Viral Liver Disease. Wiley-Blackwell, 2010. pp. 50-54
@inbook{e916ac11942444a98fd1ad3c535d5235,
title = "Management of HCV in Dialysis Patients",
abstract = "HCV infection remains frequent among patients on maintenance haemodialysis, and HCV has a detrimental role on survival in this population. Recent data have been accumulated on the antiviral treatment of HCV in dialysis patients. Although response rates to conventional interferon are better in the dialysis population, tolerance to interferon monotherapy appears lower in patients on maintenance haemodialysis than in the population with intact kidney function. The most frequent side effects requiring interruption of treatment were flu-like symptoms and gastrointestinal and haematological changes. One-third of dialysis patients with chronic HCV were successfully treated with conventional or pegylated interferon monotherapy, the summary estimate for sustained virological response rate being 39{\%} (95{\%} CI 32, 46) and 31{\%} (95{\%} CI 7, 55), respectively, according to a recent meta-analysis. Preliminary evidence does not support additional benefit of monotherapy with peginterferon on the viral response in the dialysis population. Scarce data exist on combined antiviral therapy for HCV (interferon plus ribavirin) in the dialysis population, even if encouraging results in terms of viral response have been noted. The optimal antiviral treatment of chronic hepatitis C in the dialysis population is currently under investigation.",
keywords = "Dialysis, Hepatitis C, Interferon, Survival",
author = "Fabrizio Fabrizi and Paul Martin",
year = "2010",
month = "3",
day = "10",
doi = "10.1002/9781444319590.ch11",
language = "English",
isbn = "9781405179058",
pages = "50--54",
booktitle = "Clinical Dilemmas in Viral Liver Disease",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Management of HCV in Dialysis Patients

AU - Fabrizi, Fabrizio

AU - Martin, Paul

PY - 2010/3/10

Y1 - 2010/3/10

N2 - HCV infection remains frequent among patients on maintenance haemodialysis, and HCV has a detrimental role on survival in this population. Recent data have been accumulated on the antiviral treatment of HCV in dialysis patients. Although response rates to conventional interferon are better in the dialysis population, tolerance to interferon monotherapy appears lower in patients on maintenance haemodialysis than in the population with intact kidney function. The most frequent side effects requiring interruption of treatment were flu-like symptoms and gastrointestinal and haematological changes. One-third of dialysis patients with chronic HCV were successfully treated with conventional or pegylated interferon monotherapy, the summary estimate for sustained virological response rate being 39% (95% CI 32, 46) and 31% (95% CI 7, 55), respectively, according to a recent meta-analysis. Preliminary evidence does not support additional benefit of monotherapy with peginterferon on the viral response in the dialysis population. Scarce data exist on combined antiviral therapy for HCV (interferon plus ribavirin) in the dialysis population, even if encouraging results in terms of viral response have been noted. The optimal antiviral treatment of chronic hepatitis C in the dialysis population is currently under investigation.

AB - HCV infection remains frequent among patients on maintenance haemodialysis, and HCV has a detrimental role on survival in this population. Recent data have been accumulated on the antiviral treatment of HCV in dialysis patients. Although response rates to conventional interferon are better in the dialysis population, tolerance to interferon monotherapy appears lower in patients on maintenance haemodialysis than in the population with intact kidney function. The most frequent side effects requiring interruption of treatment were flu-like symptoms and gastrointestinal and haematological changes. One-third of dialysis patients with chronic HCV were successfully treated with conventional or pegylated interferon monotherapy, the summary estimate for sustained virological response rate being 39% (95% CI 32, 46) and 31% (95% CI 7, 55), respectively, according to a recent meta-analysis. Preliminary evidence does not support additional benefit of monotherapy with peginterferon on the viral response in the dialysis population. Scarce data exist on combined antiviral therapy for HCV (interferon plus ribavirin) in the dialysis population, even if encouraging results in terms of viral response have been noted. The optimal antiviral treatment of chronic hepatitis C in the dialysis population is currently under investigation.

KW - Dialysis

KW - Hepatitis C

KW - Interferon

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84886072571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886072571&partnerID=8YFLogxK

U2 - 10.1002/9781444319590.ch11

DO - 10.1002/9781444319590.ch11

M3 - Chapter

SN - 9781405179058

SP - 50

EP - 54

BT - Clinical Dilemmas in Viral Liver Disease

PB - Wiley-Blackwell

ER -